Prothena director granted options for 27,000 shares

Prothena Corp Public Ltd Co director Lars Ekman received a grant of stock options for 27,000 ordinary shares.

Accepted by SEC EDGAR 05/15/2026 - 09:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Prothena Corp Public Ltd Co director Lars Ekman received a grant of stock options for 27,000 ordinary shares. The options have an exercise price of $9.76 per share and expire on May 15, 2036. They vest 100% on the earlier of the first anniversary of the grant date or the company’s 2027 annual general meeting, assuming he continues serving as a director until that vesting date. This is an equity compensation award rather than an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 27,000 shares

Grant/Award 1 txn

Insider Ekman Lars

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	27,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 27,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

Key Figures

Option grant size: 27,000 shares Exercise price: $9.76 per share Expiration date: May 15, 2036 +2 more

5 metrics

Option grant size 27,000 shares Stock options for ordinary shares granted to director

Exercise price $9.76 per share Strike price for stock options

Expiration date May 15, 2036 Option term end date

Shares underlying options after grant 27,000 shares Total derivative securities following transaction

Derivative transactions in filing 1 transaction Single derivative grant reported

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual general meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 9.7600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option will vest and become exercisable as to 100%"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual general meeting financial

"the day of the annual general meeting in 2027 of the Issuer's shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prothena (PRTA) director Lars Ekman report in this Form 4?

Lars Ekman reported receiving a grant of stock options for 27,000 ordinary shares of Prothena. These options are a compensation award, not an open-market trade, and give him the right to buy shares at a fixed exercise price in the future.

How many Prothena (PRTA) shares are covered by Lars Ekman’s new options?

The option grant covers 27,000 ordinary shares of Prothena. This means he can choose to buy up to 27,000 shares at the specified exercise price if and when the options vest and he decides to exercise them.

What is the exercise price of Lars Ekman’s Prothena (PRTA) stock options?

The options have an exercise price of $9.76 per share. This is the fixed price at which he may purchase Prothena ordinary shares once the options vest and before they expire, regardless of the market price at that time.

When do Lars Ekman’s Prothena (PRTA) options vest?

The options will vest and become exercisable as to 100% of the 27,000 shares on the earlier of the first anniversary of the grant date or the 2027 annual general meeting, assuming he remains a director through that vesting date.

When do Lars Ekman’s Prothena (PRTA) stock options expire?

The options expire on May 15, 2036, if not exercised earlier. After this expiration date, he will no longer have the right to purchase Prothena ordinary shares under this particular option grant.

Is Lars Ekman buying or selling Prothena (PRTA) stock in this filing?

He is not buying or selling shares in the market in this filing. Instead, he received a stock option grant as compensation, giving him the right to buy Prothena shares later at a fixed exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ekman Lars

(Last) (First) (Middle)

C/O PROTHENA BIOSCIENCES INC

1800 SIERRA POINT PARKWAY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROTHENA CORP PUBLIC LTD CO [ PRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.76	05/15/2026		A		27,000		(1)	05/15/2036	Ordinary Shares	27,000	$0	27,000	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

	/s/ Michael J. Malecek, as Attorney-in-Fact for Lars G. Ekman	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)